However, the clinical use of single agent CAIX inhibitors is likely to be hindered by the cancer cell, inducing compensatory mechanisms such as the upregulation of CAXII expression, or other acid-extruding mechanisms such as NHE1, resulting in an unsatisfactory therapeutic effect. This evidence concerns the gene SLC9A1 and cancer.